• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Ranibizumab approved for use in Europe

Article

Basel, Switzerland-The European Union has approved ranibizumab (Lucentis, Genentech) as a new treatment for patients with wet age-related macular degeneration (AMD).

Basel, Switzerland-The European Union has approved ranibizumab (Lucentis, Genentech) as a new treatment for patients with wet age-related macular degeneration (AMD).

The decision came 11 months after submission and applies to all 27 member states as well as Iceland and Norway. The company has said it will launch the drug in European countries throughout 2007 and 2008.

The drug is approved for use in Switzerland, India, and the United States. It is the first therapy shown in clinical trials to improve vision and in patients with wet AMD.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.